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Abstract: The World Health Organisation reported COPD to be the third leading cause of death
globally in 2019, and in 2020, the most common cause of cancer death was lung cancer; when these
linked conditions are added together they come near the top of the leading causes of mortality. The
cell-biological program termed epithelial-to-mesenchymal transition (EMT) plays an important role
in organ development, fibrosis and cancer progression. Over the past decade there has emerged a
substantial literature that also links EMT specifically to the pathophysiology of chronic obstructive
pulmonary disease (COPD) as primarily an airway fibrosis disease; COPD is a recognised strong
independent risk factor for the development of lung cancer, over and above the risks associated with
smoking. In this review, our primary focus is to highlight these linkages and alert both the COPD
and lung cancer fields to these complex interactions. We emphasise the need for inter-disciplinary
attention and research focused on the likely crucial roles of EMT (and potential for its inhibition) with
recognition of its strategic place mechanistically in both COPD and lung cancer. As part of this we
discuss the future potential directions for novel therapeutic opportunities, including evidence-based
strategic repurposing of currently used familiar/approved medications.
Keywords: epithelial-mesenchymal transition; chronic obstructive pulmonary disease; lung can-
cer; therapy
1. Introduction
Epithelial-mesenchymal transition (EMT) refers to a biological process in which basal
cells in a polarised epithelium with cell-cell contacts and attached to the basal membrane dif-
ferentiate into (myo) fibroblast-type mesenchymal cells [1]. This process demonstrates the
plasticity of epithelial cells that can also undergo the reverse process, i.e., the mesenchymal-
epithelial transition (MET) [2,3]. EMT involves the loss of epithelial polarity due to the
disassembly of cell-cell contacts such as adherent junctions (E-cadherin) or tight junctions
(zonula occludens-1) and, on the other hand, gain of expression of mesenchymal proteins
such as α-smooth muscle actin [4], vimentin and/or fibronectin [5,6]. Enhanced production
of extracellular matrix (ECM) components (fibronectin and collagens) and tissue matrix-
degrading enzymes, matrix metalloproteinases (MMP2 and MMP9) gives the ability to lay
down new and altered matrix which also leads to the loss of adherence to the ECM and
gives the cells a migratory capacity.
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Historically, epithelial and mesenchymal cells have been differentiated histologically
on the basis of their characteristic visual appearances and the morphology of the organised
multicellular structures they create [7]. A typical epithelium is a sheet of cells, often one
cell thick (or pseudo-stratified), with individual epithelial cells all attached to the basement
membrane, and abutting each other in a uniform array. Regularly spaced cell-cell junctions
with adhesion proteins between neighbouring epithelial cells hold them tightly together
and inhibit the movement of individual cells away from the epithelial monolayer. Mutual
adhesiveness allows an epithelial sheet to enclose a three-dimensional space and provides
it with structural definition and mechanical integrity. The epithelial sheet itself is polarized,
meaning that the apical and basal surfaces are likely to be visually different, adhere to
different substrates and have different functions [8].
Mesenchymal cells, on the other hand, generally exhibit neither regimented structure
nor tight intracellular adhesion, although they typically have intense functional interaction
with molecules in surrounding matrix. Mesenchymal cells form structures that are irregular
in shape and not uniform in composition or density. Adhesions between mesenchymal
cells are less strong than for their epithelial counterparts, allowing for increased migratory
capacity [9]. Mesenchymal cells also have a more extended and elongated shape, relative
to epithelial cells, though they possess front-to-back leading-edge polarity. Moreover,
mesenchymal migration is mechanistically different from epithelial movement; the latter
move as a sheet en-lock, whereas for the former migration is considerably more dynamic.
Mesenchymal cells move individually. Elizabeth Hay, who first described EMT, illustrated
the fundamental differences in such movement between embryogenesis (subtle/controlled)
and tumorigenesis (aggressive/uncontrolled) to define these distinct EMT mechanisms [1].
Such differences have led to division of EMT into three general types.
2. Types of EMT
Type I EMT is that involved in tissue and organ formation during embryogenesis [10],
and is implicated in the differentiation of the mesoderm from the epithelium and in the
generation of neural crest cells. In this way, the primary mesenchyme is formed from the
epiblast (primitive epithelium) [11–14].
Type II EMT is involved in non-neoplastic fibroblast recruitment in chronic inflammation-
related wound healing, tissue repair and tissue regeneration/remodelling [15–19]. How-
ever, with uncoordinated and uncontrolled tissue repair processes, EMT is associated with
tissue fibrosis; accumulated fibroblasts secrete collagen fibres, leading to organ dysfunction.
Type III EMT refers to the acquisition of a migratory phenotype by malignant epithe-
lial cells and is associated with tumour invasiveness and metastasis [20,21]. Epithelial cells
lose their polarity and detach from the basal membrane, migrate through the ECM/tissue
and detach themselves from it to reach the blood circulation to find new organ sites to
target. Metastatic cells express mesenchymal markers such as α-SMA, fibroblast specific
protein-1 (FSP1; also known as S100A4), vimentin (or desmin) [22]. These EMT markers are
particularly expressed in the cells localised in the invasion front of the tumour [3,23,24], as
demonstrated in models in ovarian, colon, oesophageal and bronchial cancers [23,25–28].
We have also reported that in smokers, though especially marked in COPD subjects,
EMT is active in airway epithelial basal cells [29,30]. Further, EMT in large airways
is characteristic of Type-III EMT on the basis of Rbm hyper-vascularity which is another
characteristic feature, thus forming a microenvironment for the development of lung cancer.
In contrast, a process more resembling Type-II EMT is predominant in small airways, thus
more pro-fibrotic and perhaps likely to be more related to small airway fibrosis, obstruction
and obliteration [30].
3. Potential Factors Driving EMT and Its Signalling Pathways
The transition of epithelial cells into mesenchymal cells, in development or patholog-
ically, follows a common and conserved programme with specific hallmarks. However,
it also has an inherent flexibility and some variation depending on the context, e.g., cell
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type, organ/tissue and the signals that activate the EMT programme; partial expression
is common. Indeed the EMT subtypes are themselves dependent on such physiological
context [16], which differentially alter basal cell gene expression and activation signatures
which define the mesenchymal phenotype. Variations occur in degree of increased cell
protrusions, due to rearrangements of the intracellular microtubule network, with switch-
ing of cytokeratin-rich to vimentin-rich networks during the EMT process. This leads to
increased motility [31], and in many cases the ability via matrix metalloprotein production
to degrade extracellular matrix (ECM) proteins which is inherent in invasive behaviour.
Additionally, cells that have undergone EMT acquire variable resistance to senescence and
apoptosis. Thus, the presence of EMT activity is recognised through the presence of such
dynamic and diverse properties of activated mesenchymal cells with active in-process
transition of epithelial cells with some residual epitopes.
A limited number of signalling pathways seems to play key roles in EMT regulation.
These include those driven by transforming growth factor (TGF), bone morphogenic protein
(BMP), fibroblast growth factor (FGF), epidermal growth factor receptor (EGFR), hepatocyte
growth factor (HGF), their frequently tyrosine-kinase trans-cell membrane receptors, and
TGFβ/SMAD, Wnt/β-catenin, and Notch pathways [32,33] (Figure 1). However, there is
considerable redundancy with common shared downstream mechanism and modulating
kinases that could be strategically targeted therapeutically.
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Figure 1. Epithelial-Mesenchymal Transition (EMT)-associated pathways/transcriptional factors as potential therapeutic
targets. External stimulus (such as cigarette smoke, pollutants, and luminal infection/inflammation) “activate” the airway
epithelium resulting in the increased production of transforming growth factor-β (TGF-β) and other EMT drivers (e.g., Wnt).
The sequence is generation of basal (stem) cell signalling molecules (e.g., β-catenin, SMADs and kinases), then elevation
of activity of gene transcription factors (e.g., Snail, Twist, Slug etc.), and finally production of EMT-related mesenchymal
proteins and suppression of normal epithelial markers.
Indeed, the cancer regulatory protein p53 and its upstream regulatory kinases also
seem to be involved in EMT activation. p53 is negatively regulated by the oxidative stress-
activated non-receptor tyrosine Src-family kinase Lyn, which has ubiquitous inflammatory
and pro-malignant roles in many organ system [34]; in epithelial cells its upregulation and
activation through phosphorylation enhances EMT activity [35]. The pathway seems to be
that Lyn activation inhibits p53 by which its direct inhibition of EMT activation is removed,
i.e., the brake on the other upstream activators which are also switched on by oxidant stress
is removed. In human airway epithelial cells from smokers there was a direct correlation
found between Lyn and EMT expression [36]. As well as p53 inhibition, this relationship of
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Lyn to EMT in airway epithelial cells may be due to increasing phosphorylation of Smad
EMT-transcription factors in the classic TGFβ1 EMT-inducing pathway, either at the Smad
level itself, or through TGFβ1-level activation of this growth factor or its tyrosine kinase
receptor system [36]. Other strategic points where effects of TGFβ1 and Wnt stimulation
converge, and also where conventional inflammatory pathways cross with EMT activation,
are the PI3K/ALF/mTOR and TGFβ-activated kinase (TAK1 or Map3k7) pathways [37,38].
These are highly complex sets of mutually cross-enhancing mechanisms which provide
ample targets for future drug therapies.
(Pre-)malignant cells undergoing EMT exhibit both morphological changes and molec-
ular alterations, as observed by decreased epithelial markers expression, including E-
cadherin, ZO-1, and occludin, and increased expression of mesenchymal markers, in-
cluding, S100A4, vimentin, N-cadherin and fibronectin [29,30,39,40]. Boutet et al. have
also reported up-regulation of several EMT-associated transcription factors in metastatic
cells, including Snail, Twist, Zeb, and others. TGF-β plays a large role in activating Snail,
which in turn down-regulates cadherin-16 and HNF-1β which seems to enhance the move
to EMT [41].
In addition to the specific EMT-signature transcription factor programs (e.g., SMAD,
Snail, Zeb, Twist, etc.), particular miRNAs with either pro- and anti-EMT activity (such
as miR-200, miR-205 and miR-21) and also epigenetic regulators have become evident
in regulation of EMT-inducing cell plasticity and phenotypic alteration during carcino-
genesis [42]. As well as promoting the transformation of early stage primary tumours
into invasive malignancies, EMT has also been implicated in the very generation of such
early stage cancer cells with stem cell-like characteristics. These subtypes of cells not
only exhibit increased tumour-initiating capabilities but also potential for self-renewal
(tumour recurrence), and EMT-related resistance to apoptosis and to chemotherapeutic
agents [43–45]. Such EMT involvement in primary carcinogenesis as well as in accelerated
tumour spread and metastasis subsequently has been studied in epithelial cancer stem cells
(CSC) in breast [46], pancreatic [47], colorectal [48] and prostate cancer [49], although data
are currently still limited for NSCLC. This issue of a primary cancerogenic role for EMT in
lung cancer urgently needs further clarification.
4. Identification of EMT
Identification of EMT requires a selection of specific immune-markers, but also de-
tailed review of classic phenotypic changes in the state of the tissue. In COPD for instance,
we were alerted to the possibility of active airway EMT by observing an irregular and
fragmented epithelial reticular basement membrane which was hyper-cellular and hyper-
vascular [30]. This was confirmed by loss of the epithelial phenotype in basal cells as
characterised by decrease in the expression of epithelial proteins including junction pro-
teins (E-cadherin and zonula occludens-1), cytokeratins of the cytoskeleton and a decreased
expression of the surface protein MUC1 (Mucin 1, cell surface associated). Although the
loss of these proteins has been widely described during EMT, the acquisition of mesenchy-
mal markers is slower and more difficult to prove. However, markers available for defining
the mesenchymal phenotype are vimentin, α-SMA, fibroblast specific protein (FSP1 or
S100A4), desmin, fibronectin and the production of MMPs [50]. Nonetheless, vimentin is
not expressed by all fibroblasts and is also present in leukocytes and endothelial cells [51].
α-SMA is expressed by myofibroblasts that normally represent only a fraction of the ac-
tivated fibroblasts, but these increase markedly in the presence of EMT [52–54]. Finally,
FSP1 (S100A4) is expressed by inflammatory cells, as well as endothelial cells and smooth
muscle cells [55–58]. This non-specificity of mesenchymal markers highlights the difficulty
in confirming the presence of EMT, and the need to use multiple markers to characterise the
process, and also if possible to double stain for both epithelial markers and a mesenchymal
marker in the same transitioning cell. Thus, in COPD we found such co-expression in cells
in the basal epithelial area and also in clefts in the reticular basement membrane cells [29].
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5. EMT and Tumour Metastasis
The importance of the EMT program in tumour development and progression has
been established in the past two decades with a rapidly growing number of studies demon-
strating its activation during the process of malignant progression [44,59]. We have already
made the point that more work is needed in lung cancer on whether EMT is involved in
the primary epithelial cancer development [33].
In the epithelial carcinomas, in which the contributions of the EMT program to
cancer cell phenotypes have been most intensively studied, EMT-induced mesenchymal
traits seems to enable carcinoma cells to complete many of the steps in the invasion-
metastasis cascade, including the local invasion by neoplastic cells at the primary tumour
site, intravasation into blood vessels, translocation through the circulation, extravasation
into the parenchyma of distant tissues, and survival as micrometastatic deposits [3,60].
As noted above in the context of non-malignant cells, it is also rare for carcinoma cells
to lose all epithelial traits and gain a full spectrum of mesenchymal characteristics. An
important, though rare, variant, reflecting the same principle of heterogeneity, is provided
by carcino-sarcomas, in which distinct epithelial and mesenchymal compartments coexist
in the tumour although derived from a common cellular precursor [61].
More than 90% of cancer-associated deaths are associated with metastatic disease
rather than by the localized primary tumours [60,62]. The increased motility/invasiveness
associated with the mesenchymal cell has linked this tumour metastasis with expression of
the malignant cell’s EMT program, in which individual cell separation from the primary
tumour mass can be considered as the first step of the invasion-metastasis cascade [60].
In addition, a majority of studies using both mouse models and human cancer cell-line
culture have demonstrated that induction of an EMT program allows carcinoma cells
to lose cell-cell junctions, degrade local basement membrane via elevated expression of
various matrix-degrading enzymes, e.g., MMPs, and access to regional blood vessels,
as evidence of migration and invasion as single cells [63–66]. Further histopathological
analysis has revealed that at the tumour invasive front, which is in close proximity to the
desmoplastic stroma, a higher proportion of cells express an EMT phenotype with loss
of epithelial markers and cell-cell junctions and increased expression of mesenchymal
markers [23,39,67,68].
Further, EMT-mediated neo-angiogenesis has been proposed as a mechanism of en-
hanced dissemination of tumour cells into the systemic circulation [69]. However, the
notion that cells with EMT phenotypes preferentially disseminate into the circulation is
contradicted by the findings that both epithelial and mesenchymal cells are found in the
peripheral blood [70]. Thus, other modes of cell migration, including passive shedding [71],
collective and clustered migration [72], early dissemination at the stage of carcinoma
in situ [73], and migration into vascularized areas inside the tumour mass, have been
suggested as contributing to tumour dissemination. These are not mutually exclusive
mechanisms, however, and movement of individual cells between phenotypic epithe-
lial and mesenchymal appearances may well occur at different stages of the individual
cells’s journey.
6. EMT-MET Interaction
Thus, as well as EMT, its reversal process of mesenchymal-to-epithelial transition
(MET) has been suggested to play important roles in metastatic dissemination of carcino-
mas, so that in different phases during the metastatic process carcinoma cells can attain
either a fully epithelial or a fully mesenchymal state [3]. This allows tumour cells that
have a motile EMT phenotype to allow intravasation of blood capillaries at the primary
tumour site and also to extravasate into the distant organ, in general must revert back
to a largely epithelial phenotype in order to grow optimally in the secondary site and
become a clinically relevant and detectable mass. Indeed, it has been suggested that there
is mutual cooperation between epithelial and mesenchymal cell phenotypes such that
the mesenchymal form just “paves the way” [74]. Although scarce, there is evidence
Biomolecules 2021, 11, 1394 6 of 15
supporting the notion that CTCs could be used as an early diagnostic tool to monitor lung
cancer initiation in patients with COPD [75]. Unfortunately, the study was limited by
small number of participants, i.e., CTCs were detected in only 3% (5 out of 168) of COPD
patients. Nonetheless, a small number of CTCs exhibited expression of vimentin with a
weak associated cytokeratin expression. This indicates that monitoring CTCs in ‘at risk’
COPD patients could be useful in early detection of lung cancer, however, larger studies
are needed to test and confirm these findings.
It is likely that it is fluctuating activity of EMT-TFs and microRNA families that
regulate EMT which causes this full or sometimes partial switching between EMT and
MET cancer cell phenotype phases [76]. However, detailed discussion of the literature on
this is beyond the scope of this article. Further, MET-independent metastasis do occur but
the mechanisms involved in these cases remain elusive. More information on the control
mechanism involved here could be important in stimulating new therapeutic strategies.
7. Lung Cancer
Histologically, lung cancer is characterised into two main types: small cell carcinoma
and non-small cell carcinoma (the latter including especially adeno and squamous cell
carcinoma). Pathological association of smoking with the development of COPD and
then lung cancer in that group, is of high clinical significance. This association may well
have links with EMT and its downstream pathways. We have observed that the EMT
in large airways in smokers is ubiquitous, and characteristic of so-called Type-III EMT
with angiogenesis in the reticular basement membrane and epithelium, while Type-II
EMT is predominant in small airways, i.e., without new and abnormal blood vessels.
As mentioned earlier, this is consistent with the major smoking-related pathologies in
the two compartments: in large airways the development of lung cancer, while in small
airway obstruction and obliteration (perhaps as well as cancer) [30]. We have failed to find
differences in EMT activity between squamous cell- and adeno-carcinomas [39], nor in
the relationship between EMT activity in the tumours versus the large and small airways
from which they are likely to have emerged [39]. Whether Type-II EMT in the small
airways is also in fact pro-cancer development is another area where further work is
needed for clarification.
Shi and colleagues were the first to report that in lung cancer cells, poor patient out-
comes were correlated with elevated EMT markers [77]. Interestingly, fibroblasts associated
with lung cancer (CAF) demonstrated microarray gene expression of proteins regulated
by TGF-β [78]. Thus, TGF-β is a master regulator of cancer development operative at a
number of levels and not only directly at stimulating EMT [79]. Sustained TGF-β signalling
(for example by autocrine signalling to drive sustained zinc finger protein ZEB expression
and resultant reduced levels and activity of miR200, through its DNA methylation) may be
required for the maintenance of EMT and also for metastasis in several mouse lung cancer
models [80–82]. At the same time, lung cancer somehow avoids the autocrine growth
inhibitory effect of TGF-β2 in most NSCLC and SCLC, and restoration of this anomaly
might be a potential target for therapeutic intervention [83,84].
Another EMT driver, Wnt signalling, has been demonstrated in many cancers and
has recently emerged as a critical pathway in lung carcinogenesis. Cells expressing Wnt-1
are resistant to therapies that mediate apoptosis. Wnt-1 and Wnt-2 have been found to
be over-expressed in NSCLC lines and other primary tumour tissues. In addition, an
anti-Wnt-1 monoclonal antibody has been shown to suppress tumour growth [85].
We know that both SCLC and NSCLC require an active Hh signalling pathway, yet
another route into EMT. Furthermore, it has been shown that an antagonist of the Hh
pathway inhibits proliferation of NSCLC cell lines with an Hh autocrine loop. How-
ever, Hh signalling in lung cancer may also feed into control of cell proliferation, and
provison of a viable blood supply via VEGF and platelet-derived growth factor (PDGF)
signalling pathways [86].
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Notch signalling, also frequently associated with EMT gene-programme activation,
is also required for lung cancer development, as illustrated by studies on knockout mice.
Notch receptors and ligand are both elevated in NSCLC lines. Blockade of Notch pathway
activation, using gamma secretase inhibition, shows increased apoptosis and reduced
in vivo and in vitro NSCLC tumour growth [87]. However, in contrast, forced activa-
tion of Notch signalling in tumour-associated macrophages enhanced their anti-tumour
capacity [88].
A recent study by Marzieh Rezaei etal highlighted an association of Human Papil-
lomavirus (HPV) infection with EMT-associated lung cancer development. They demon-
strated high expression of EMT-promoting HPV genes (E-2, E6 and E7), high TGF-β and
N-cadherin expression in HPV + ve lung cancer patients. Similarly, Slug gene overexpres-
sion along with resultant E-cadherin gene down-regulation was marked in HPV-associated
lung cancer. These EMT molecular signatures were strongly correlated with the stage of
lung cancer, being more in stage IV and lowest in stage IA and IB [89].
We have already dealt with the interaction of Lyn kinase activation and inhibition
of the anti-epithelial cancer protein p53, with then knock-on effects on EMT by taking
off this anti-EMT brake. Further, and as discussed, Lyn is also likely to interact with the
TGF-β/Smad pathway. Not much is yet known about the relative importance of these
and other complex kinase systems and whether they have independent effects on cancer
development or whether this is all or at least mainly mediated through EMT activation.
Finally for this section, a novel human finding [39] was that EGFR and expression of
EMT-related proteins were markedly high at the peripheral leading edge of NSCLCs, both
adeno and squamous-cancers and related to tumour and clinical characteristics associated
with poor prognosis. There is a potential here for developing prognostic markers. The
relationships between degree of EMT-related tumour bio-marker expression and those in
the corresponding airway epithelium and reticular basement membrane, suggest that the
airway microenvironment from which the tumour arises influence the cancer’s subsequent
natural history.
8. COPD and Lung Cancer
There has been a quite a number of individual studies over the past two decades
showing now convincingly that COPD itself is a strong risk factor for lung cancer, and
importantly, to be independent of the smoking that caused the COPD, although of course
this and other common background factors can be challenging to untangle [90,91]. The
consensus quantitative increase in risk for lung cancer with COPD is 5-fold; meaning that
up to 70% of lung cancers could be related to COPD. It is very possible that this is an
underestimate and indeed the majority of COPD worldwide may be undiagnosed [92].
In addition, the disease has its predominant physiological effect in the small airways
but the conventional way of detecting COPD with spirometry underestimates this quite
appreciably [93]. Of course, very many smokers never get to have lung function in the first
place [94]. Analysis of genetic influences that bring together COPD and lung cancer risk is
beyond the scope of this paper, but we recently reviewed this mutuality in the context of
more broadly covering COPD pathogenesis [33].
We have already alluded to our human tissue findings of airway epithelial EMT
activity in smokers. Invariably this is even greater in subjects with COPD [33]. Furthermore,
we have teased out the roles of TGβ/Smad and β-catenin-Snail1-Twist pathways, and
the strong relationship between EMT activity and degree of obstructive lung function
abnormality [33,39].
9. Drugs That Affect Both COPD and Lung Cancer and Their Interrelationship
Even more intriguing is the growing evidence for a protective effect of inhaled cor-
ticosteroid (ICS) against lung cancer risk in COPD. Ge et al. [95] recently systematically
reviewed nine studies incorporating almost 182,000 COPD patients, representing 1.1 mil-
lion person-years. This showed a relatively uniform reduction in cancer risk of 30% with
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ICS use. However, this is likely an underestimate of the effect, as shown by Raymak-
ers et al. [96] the actual protective effect is closer to 70% if the first 2 years of ICS use are
excluded from such analyses to take into account cancers already developed.
Statins have long been thought of as potentially useful in COPD, both in terms of
morbidity and mortality, but have not been taken up for this indication [61]. As for
ICS, there is also strong population pharmaco-epidemiological evidence that statin use
(aimed at cholesterol reduction) coincidentally reduces the risk of lung cancer in COPD,
especially for NSCLC. This effect is again large, with about a 40–60% reduction in cancer
development if again a 2 year use threshold is applied and if medication is used for more
than 6 months [97,98]; this effect varies with dose and lipophilicity of specific drugs [97,98].
Further, survival in lung cancer patients is significantly better, by up to 20% if they are
co-incidentally taking statins post-operatively [99].
Although an airway luminal anti-innate inflammatory effect has been the favoured
theory for these cancer-protective effects of ICS and statins, there is little evidence for this,
although an anti-inflammatory effect may contribute to reducing oxidative stress and thus
activation of the epithelium, although the exact mechanisms by which anti-inflammatories
impart this effect is not yet known in the context of COPD-lung cancer. However, in in vitro
cancer cell cultures both drugs have an inhibitory effect on malignancy status through
influencing the usually mutually inhibitory balance between the anti-cancer protein p53
and pro-malignant epithelial basal cell EMT activity [34,100–102]. There is a sting in this
tail, in that with particular mutations in the p53 gene the interaction between p53 and EMT
may be positive and the effect of statins acceleratory [102].
In vivo human data is difficult to obtain, but in a small proof-of-concept RCT of high
dose ICS using airway biopsy in COPD patients, Sohal et al. showed an inhibitory effect
on EMT markers in airway epithelium [103]. In the same study analysis of EMT-related
blood vessels, part of the pro-malignant airway environment, showed reversion towards
normal with ICS [104].
10. Potential EMT-Targeted Therapies
It is our contention, based on the balance of evidence as we see it, that EMT plays a
major (and possibly fundamental) pathogenic role in COPD airway remodelling disease,
AND related lung cancer development. However, there may be a number of pathways
activated by oxidant stress on the airway epithelium, for which EMT may be the final
common pathway into airway remodelling and obstruction/obliteration as well as tumori-
genesis. Because of the upstream complexity, it might be that drugs directly inhibiting
the EMT process should be the first to be trialled for prevention of COPD/lung cancer in
vulnerable people.
Fortunately, EMT is now increasingly being considered as treatable and thus being
targeted in various stages of drug development (Table 1). Notably, multiple EMT-related
drugs have been emerging over the last decade in the oncology literature [105–109], with
seven more in PubMed just in the last year, with one directed specifically at NSCLC [110].
Meanwhile in IPF, anti-fibrotic drugs (such as nintedanib and pirfenidone) which seem
to work through inhibition of TGF-β pathways [111] have been introduced with effect.
All of these drug modalities hold great promise for translation to inhibition of COPD
development and through that prophylaxis against lung cancer.
However, the drugs already used for short-term objectives in COPD may themselves
be strategically repurposed to focus on their own long-term anti-EMT preventive actions;
these might be directed at EMT pathways themselves and/or through damping innate
luminal inflammation and its contribution to airway oxidant burden. As noted earlier, it
is notable that inhaled corticosteroids (ICS) have been suggested as being both protective
in lung cancer and specifically inhibitory of EMT in human airways [90,98]. Long-acting
β-agonists (LABAs), long-acting muscarinic antagonists (LAMAs) and phosphodiesterase
(PDE)-inhibitors may also contribute to a direct anti-EMT effect [40], as might urokinase-
type plasminogen activator receptor (uPAR) inhibition [112].
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Table 1. Some of the Molecules designed for Targeting EMT in Lung Cancer.




Bufalin TGF-βpathway EMT inhibition NSCLC Preclinical
SU11274 C-Met Overcomes resistance toEGFR-targeted therapies NSCLC Preclinical
RO4929097 Notchsignalling
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As we have discussed, statins also decrease lung cancer risk while being shown to
reduce EMT activity and through this cancer aggressiveness [105–109]. Designer small
molecules which inhibit the epigenetic reader BRD4 have been shown to switch off EMT
activity and airway remodelling via a TGF-β related mechanism [113]. The same could
be said for the anti-EMT and anti-cancer effects of the multi-biological mTOR modulator
Resveratrol [114]. miRNAs are also being directed at this mTOR target [38]. It has also
been shown that humble aspirin has potent anti-EMT action in NSCLC cells by decreasing
mTOR expression via p300 acting on its promotor region [115]. Interestingly, another more
specific COX2 cyclooxygenase inhibitor, celecoxib, inhibits EMT in epithelial tumour cells
through miRNA-145 down-regulation of the TGFβ-receptor and the Smad pathway [116].
Indeed, the possibilities for anti-EMT therapeutic interventions in long-term preven-
tive anti-lung cancer clinical studies are so wide that much thought will be needed about
where to start; perhaps ICS (or even better triple once a day ICS/LABA/LAMA combina-
tion) plus a lipophilic statin would be a good place, given their widespread use and safety
record already in COPD patients.
11. Conclusions
We would suggest that the very concept of COPD, and its therapeutic culture, needs
major reconsideration and reworking. The diagnosis of COPD at a particular physiological
cut-off is arbitrary and ignores the major recent insight that smoking-related airway disease
starts years before FEV1 declines or significant symptoms start and take the patient to their
doctor. Yet, current management guidelines and practice essentially focus almost exclu-
sively on symptoms and acute exacerbations which are really manifestations of advanced
disease. As discussed above, inter-disciplinary research suggests strong common links
between EMT, COPD and lung cancer, and the mechanisms involved are beginning to be
well understood. However, these concepts are still not fully integrated into the mainstream.
We would suggest that there should be a corresponding paradigm change for drug
treatment of COPD. This should target primary preventive therapeutic strategies, with
mediation(s) introduced prophylactically at a much earlier stage in middle age, and to
address basic pathogenic mechanism of both airway destruction/obstruction and the
concurrent lung cancer risk. Those selected for trials of this approach in the first instance
would be those who can be shown with spirometric monitoring to have a more rapid
“pre-COPD” downhill trajectory of lung function airflow indices [117].
Thus, it may well be that our current focus on short-term symptomatic outcomes, with
a pathogenic emphasis on airway luminal cellular innate inflammatory changes rather
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than long-term airway remodelling and related cancerogenesis, has led to us to overlook
the potential for repurposing commonly used COPD/asthma drugs and with a different
timescale and a new preventive strategic purpose. As well as a potential for repurposing
existing drugs, our suggested re-evaluation of the COPD paradigm also suggests trialling
of novel anti-EMT drugs already in the pipeline.
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